Elyse O Kharbanda1, Gabriela Vazquez-Benitez1, Heather S Lipkind2, Nicola P Klein3, T Craig Cheetham4, Allison Naleway5, Saad B Omer6, Simon J Hambidge7, Grace M Lee8, Michael L Jackson9, Natalie L McCarthy10, Frank DeStefano10, James D Nordin1. 1. HealthPartners Institute for Education and Research, Minneapolis, Minnesota. 2. Obstetrics and Gynecology, Yale University, New Haven, Connecticut. 3. Kaiser Permanente of Northern California, Oakland. 4. Kaiser Permanente Southern California, Pasadena. 5. Kaiser Permanente Northwest, Portland, Oregon. 6. Kaiser Permanente Georgia, Atlanta. 7. Institute for Health Research, Kaiser Permanente Colorado, Denver8Department of Ambulatory Care Services, Denver Health, Denver, Colorado. 8. Harvard Pilgrim Health Care Institute, Boston, Massachusetts10Harvard Medical School, Boston, Massachusetts. 9. Group Health Cooperative, Seattle, Washington. 10. Centers for Disease Control and Prevention, Atlanta, Georgia.
Abstract
IMPORTANCE: In 2010, due to a pertussis outbreak and neonatal deaths, the California Department of Health recommended that the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) be administered during pregnancy. Tdap is now recommended by the Advisory Committee on Immunization Practices for all pregnant women, preferably between 27 and 36 weeks' gestation. Limited data exist on Tdap safety during pregnancy. OBJECTIVE: To evaluate whether maternal Tdap vaccination during pregnancy is associated with increased risks of adverse obstetric events or adverse birth outcomes. DESIGN AND SETTING: Retrospective, observational cohort study using administrative health care databases from 2 California Vaccine Safety Datalink sites. PARTICIPANTS AND EXPOSURES: Of 123,494 women with singleton pregnancies ending in a live birth between January 1, 2010, and November 15, 2012, 26,229 (21%) received Tdap during pregnancy and 97,265 did not. MAIN OUTCOMES AND MEASURES: Risks of small-for-gestational-age (SGA) births (<10th percentile), chorioamnionitis, preterm birth (<37 weeks' gestation), and hypertensive disorders of pregnancy were evaluated. Relative risk (RR) estimates were adjusted for site, receipt of another vaccine during pregnancy, and propensity to receive Tdap during pregnancy. Cox regression was used for preterm delivery, and Poisson regression for other outcomes. RESULTS: Vaccination was not associated with increased risks of adverse birth outcomes: crude estimates for preterm delivery were 6.3% of vaccinated and 7.8% of unvaccinated women (adjusted RR, 1.03; 95% CI, 0.97-1.09); 8.4% of vaccinated and 8.3% of unvaccinated had an SGA birth (adjusted RR, 1.00; 95% CI, 0.96-1.06). Receipt of Tdap before 20 weeks was not associated with hypertensive disorder of pregnancy (adjusted RR, 1.09; 95% CI, 0.99-1.20); chorioamnionitis was diagnosed in 6.1% of vaccinated and 5.5% of unvaccinated women (adjusted RR, 1.19; 95% CI, 1.13-1.26). CONCLUSIONS AND RELEVANCE: In this cohort of women with singleton pregnancies that ended in live birth, receipt of Tdap during pregnancy was not associated with increased risk of hypertensive disorders of pregnancy or preterm or SGA birth, although a small but statistically significant increased risk of chorioamnionitis diagnosis was observed.
IMPORTANCE: In 2010, due to a pertussis outbreak and neonatal deaths, the California Department of Health recommended that the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) be administered during pregnancy. Tdap is now recommended by the Advisory Committee on Immunization Practices for all pregnant women, preferably between 27 and 36 weeks' gestation. Limited data exist on Tdap safety during pregnancy. OBJECTIVE: To evaluate whether maternal Tdap vaccination during pregnancy is associated with increased risks of adverse obstetric events or adverse birth outcomes. DESIGN AND SETTING: Retrospective, observational cohort study using administrative health care databases from 2 California Vaccine Safety Datalink sites. PARTICIPANTS AND EXPOSURES: Of 123,494 women with singleton pregnancies ending in a live birth between January 1, 2010, and November 15, 2012, 26,229 (21%) received Tdap during pregnancy and 97,265 did not. MAIN OUTCOMES AND MEASURES: Risks of small-for-gestational-age (SGA) births (<10th percentile), chorioamnionitis, preterm birth (<37 weeks' gestation), and hypertensive disorders of pregnancy were evaluated. Relative risk (RR) estimates were adjusted for site, receipt of another vaccine during pregnancy, and propensity to receive Tdap during pregnancy. Cox regression was used for preterm delivery, and Poisson regression for other outcomes. RESULTS: Vaccination was not associated with increased risks of adverse birth outcomes: crude estimates for preterm delivery were 6.3% of vaccinated and 7.8% of unvaccinated women (adjusted RR, 1.03; 95% CI, 0.97-1.09); 8.4% of vaccinated and 8.3% of unvaccinated had an SGA birth (adjusted RR, 1.00; 95% CI, 0.96-1.06). Receipt of Tdap before 20 weeks was not associated with hypertensive disorder of pregnancy (adjusted RR, 1.09; 95% CI, 0.99-1.20); chorioamnionitis was diagnosed in 6.1% of vaccinated and 5.5% of unvaccinated women (adjusted RR, 1.19; 95% CI, 1.13-1.26). CONCLUSIONS AND RELEVANCE: In this cohort of women with singleton pregnancies that ended in live birth, receipt of Tdap during pregnancy was not associated with increased risk of hypertensive disorders of pregnancy or preterm or SGA birth, although a small but statistically significant increased risk of chorioamnionitis diagnosis was observed.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Flor M Munoz; Anthony J Greisinger; Oscar A Wehmanen; Melanie E Mouzoon; James C Hoyle; Frances A Smith; W Paul Glezen Journal: Am J Obstet Gynecol Date: 2005-04 Impact factor: 8.661
Authors: Pranita D Tamma; Kevin A Ault; Carlos del Rio; Mark C Steinhoff; Neal A Halsey; Saad B Omer Journal: Am J Obstet Gynecol Date: 2009-10-21 Impact factor: 8.661
Authors: Trudy V Murphy; Barbara A Slade; Karen R Broder; Katrina Kretsinger; Tejpratap Tiwari; Patricia M Joyce; John K Iskander; Kristin Brown; John S Moran Journal: MMWR Recomm Rep Date: 2008-05-30
Authors: Karen R Broder; Margaret M Cortese; John K Iskander; Katrina Kretsinger; Barbara A Slade; Kristin H Brown; Christina M Mijalski; Tejpratap Tiwari; Emily J Weston; Amanda C Cohn; Pamela U Srivastava; John S Moran; Benjamin Schwartz; Trudy V Murphy Journal: MMWR Recomm Rep Date: 2006-03-24
Authors: Paula M Frew; Laura A Randall; Fauzia Malik; Rupali J Limaye; Andrew Wilson; Sean T O'Leary; Daniel Salmon; Meghan Donnelly; Kevin Ault; Matthew Z Dudley; Vincent L Fenimore; Saad B Omer Journal: Hum Vaccin Immunother Date: 2018-02-15 Impact factor: 3.452
Authors: Haedi DeAngelis; Samuel V Scarpino; Meagan C Fitzpatrick; Alison P Galvani; Benjamin M Althouse Journal: JAMA Pediatr Date: 2016-05-01 Impact factor: 16.193
Authors: Allison T Chamberlain; Katherine Seib; Kevin A Ault; Eli S Rosenberg; Paula M Frew; Marielysse Cortes; Ellen A S Whitney; Ruth L Berkelman; Walter A Orenstein; Saad B Omer Journal: Hum Vaccin Immunother Date: 2016-04-15 Impact factor: 3.452
Authors: Gabriela Vazquez-Benitez; Elyse O Kharbanda; Allison L Naleway; Heather Lipkind; Lakshmi Sukumaran; Natalie L McCarthy; Saad B Omer; Lei Qian; Stanley Xu; Michael L Jackson; Vinutha Vijayadev; Nicola P Klein; James D Nordin Journal: Am J Epidemiol Date: 2016-07-22 Impact factor: 4.897